background
patient
infect
influenza
viru
present
acut
lung
injuri
ali
due
sever
pneumonia
system
inflamm
often
fatal
effect
treatment
option
complement
activ
implic
pathogenesi
virusinduc
lung
injuri
therefor
investig
effect
target
complement
inhibit
ali
induc
viru
infect
method
novel
neutral
specif
antihuman
antibodi
use
antibodi
block
abil
induc
granulocyt
express
affect
abil
form
membran
attack
complex
african
green
monkey
inocul
viru
treat
intraven
result
viru
infect
led
intens
ali
system
inflammatori
respons
syndrom
sir
associ
excess
complement
activ
treatment
monkey
substanti
attenu
ali
markedli
reduc
lung
histopatholog
injuri
decreas
lung
infiltr
macrophag
neutrophil
moreov
treatment
decreas
intens
sir
bodi
temperatur
chang
minim
plasma
level
inflammatori
mediat
markedli
reduc
treatment
also
significantli
decreas
viru
titer
infect
lung
conclus
antihuman
antibodi
treatment
remark
reduc
ali
system
inflamm
induc
viru
infect
complement
inhibit
may
promis
adjunct
therapi
sever
viral
pneumonia
indexhtml
sever
case
present
viral
pneumonia
acut
lung
injuri
ali
progress
sever
respiratori
failur
acut
respiratori
distress
syndrom
ard
diseas
resembl
diseas
patient
infect
highli
pathogen
avian
influenza
viru
sever
acut
respiratori
syndrom
sar
viru
date
therapeut
strategi
effect
treat
diseas
found
complement
one
innat
immun
system
respons
host
defens
pathogen
invas
clearanc
potenti
damag
cell
debri
howev
excess
complement
activ
may
detriment
contribut
uncontrol
inflammatori
respons
lead
tissu
damag
complement
interest
promis
target
treatment
clinic
diseas
associ
excess
complement
activ
ischemiareperfus
injuri
transplantationrel
autoimmun
disord
complement
activ
may
also
use
target
viru
infectionrel
inflammatori
syndrom
gener
support
sever
studi
suggest
patient
sever
pandem
viru
infect
exhibit
complement
activ
close
associ
proinflammatori
mediat
level
lung
injuri
sever
addit
previou
studi
mous
model
infect
show
lung
tissu
section
plasma
sampl
infect
mice
markedli
elev
level
complement
activ
product
thu
although
complement
activ
need
clear
pathogen
respons
could
excess
could
lead
inflamm
tissu
injuri
ali
complement
activationinhibit
treatment
pathogenassoci
inflammatori
disord
must
thu
preserv
pathogen
clearanc
function
immun
arm
inhibit
inflamm
tissu
injuri
complement
activ
product
potent
proinflammatori
polypeptid
mediat
strong
proinflammatori
immunomodulatori
signal
mani
diseas
model
date
mani
therapeut
compound
target
receptor
test
preclin
model
show
promis
therapeut
potenti
transplant
sepsi
arthriti
renal
vascul
cancer
antibodi
blockad
also
abrog
excess
immun
respons
mous
model
plasmodium
berghei
anka
infect
inde
particularli
interest
target
molecul
treat
pathogeninduc
inflammatori
disord
block
would
like
inhibit
excess
inflammatori
respons
leav
membran
attack
complex
mac
format
intact
studi
use
monoclon
antibodi
mab
african
green
monkey
model
viru
infect
explor
whether
virusinduc
sever
pneumonia
could
treat
inhibit
data
show
treatment
remark
reduc
ali
system
inflamm
complement
inhibit
may
promis
adjunct
therapi
sever
viral
pneumonia
studi
use
human
plasma
healthi
individu
zymosanactiv
normal
human
plasma
approv
ethic
committe
beij
institut
microbiolog
epidemiolog
procedur
compli
declar
helsinki
written
consent
obtain
plasma
donor
ethic
committe
approv
consent
procedur
procedur
involv
anim
approv
institut
anim
care
use
committe
iacuc
beij
institut
microbiolog
epidemiolog
iacuc
permit
studi
anim
carri
strict
accord
recommend
guid
care
use
laboratori
anim
mab
highli
potent
neutral
mab
specif
human
develop
inflarx
gmbh
germani
treatment
inflammatori
diseas
wwwinflarxcom
clinic
phase
trial
demonstr
safe
well
toler
display
desir
pharmacokinet
pharmacodynam
paramet
phase
clinic
trial
regist
europ
http
www
materi
kindli
provid
inflarx
free
aliquot
stock
influenza
viru
strain
grown
embryon
egg
experi
involv
viru
perform
approv
biosafeti
level
facil
twelv
african
green
monkey
use
studi
ten
monkey
inocul
intratrach
tissu
cultur
infect
dose
tcid
viru
remain
monkey
mockinfect
four
virusinfect
monkey
treat
intraven
mgkg
remain
monkey
receiv
sham
intraven
treatment
detail
inform
see
supplementari
materi
method
express
granulocyt
analyz
flow
cytomet
total
hemolyt
complement
activ
ch
assay
standard
method
rel
express
mannosebind
proteinassoci
serin
proteas
masp
detect
analyz
use
ct
method
lung
viral
titer
determin
tcid
describ
previous
inflammatori
cytokin
level
monkey
plasma
sampl
measur
enzymelink
immunosorb
assay
elisa
infiltr
macrophag
neutrophil
perform
assess
immunohistochem
stain
method
previous
describ
detail
assay
use
studi
see
supplementari
materi
method
statist
analys
perform
use
graphpad
prism
version
see
supplementari
materi
method
inform
biolog
activ
antibodi
abil
block
activ
human
test
use
assay
decreas
express
human
granulocyt
antibodi
antigen
ie
endogen
molar
ratio
use
figur
nm
block
zymosanactiv
plasma
zap
driven
upregul
monkey
granulocyt
figur
abil
block
mac
format
human
monkey
sera
test
use
ch
assay
measur
abil
plasma
lyse
antibodyprim
sheep
erythrocyt
eight
human
plasma
sampl
test
without
figur
heatinactiv
plasma
figur
biolog
effect
block
human
activ
assay
perform
incub
human
blood
zymosanactiv
plasma
zap
andor
mean
standard
error
mean
sem
separ
experi
conduct
donor
n
buffer
control
group
n
group
shown
p
determin
analysi
varianc
dunnett
posttest
b
block
monkey
endogen
activ
assay
perform
monkey
zap
blood
sampl
monkey
mean
sem
group
shown
c
interfer
abil
human
plasma
induc
membran
attack
complex
mac
format
total
hemolyt
complement
activ
ch
test
perform
human
plasma
sampl
variou
concentr
heatinactiv
plasma
serv
neg
control
impact
macinduc
activ
monkey
plasma
ch
test
perform
monkey
plasma
sampl
variou
concentr
heatinactiv
plasma
serv
neg
control
abbrevi
hu
human
isotyp
control
mfi
mean
fluoresc
intens
neg
control
induc
lysi
dilut
wherea
untreat
plasma
potent
lyse
erythrocyt
howev
dose
rang
influenc
mac
format
similar
data
obtain
monkey
plasma
figur
thu
potent
inhibit
inflammatori
respons
human
monkey
without
impair
format
mac
unlik
mockinfect
monkey
virusinfect
monkey
treat
exhibit
extens
damag
lung
day
viral
infect
name
multifoc
tracheal
bronchaden
figur
bronchu
alveoli
reveal
acut
exud
diffus
pulmonari
damag
denatur
collaps
epitheli
tissu
figur
diffus
thicken
alveolar
septa
figur
moreov
endotheli
tissu
lung
denatur
exhibit
larg
number
adher
inflammatori
cell
damag
basement
membran
figur
ultrastructur
analysi
alveoli
reveal
degener
pulmonari
epitheli
cell
damag
bloodga
barrier
figur
lung
tissu
virusinfect
mockinfect
monkey
kill
day
subject
realtim
revers
transcript
polymeras
chain
reaction
analysi
express
inde
gene
significantli
upregul
infect
monkey
figur
c
plasma
level
major
complement
activ
product
rose
sharpli
infect
notabl
although
level
remain
high
time
point
day
level
drop
peak
day
return
baselin
day
figur
immunohistochemistri
lung
day
also
reveal
elev
protein
express
lung
especi
bronchiol
epithelium
sever
inflam
lung
tissu
figur
lung
also
exhibit
increas
level
anoth
indic
complement
activ
figur
thu
complement
system
extens
activ
circul
lung
infect
investig
role
complement
activ
pathogenesi
infectioninduc
lung
injuri
shamtreat
monkey
sacrif
day
viru
inocul
gross
patholog
reveal
lung
shamtreat
monkey
exhibit
multifoc
consolid
dark
red
discolor
particularli
preval
dorsal
surfac
lung
figur
contrast
lung
monkey
look
almost
normal
littl
dark
red
discolor
figur
similarli
histopatholog
analysi
show
day
infect
shamtreat
monkey
develop
pulmonari
damag
mild
multifoc
bronchointerstiti
pneumonia
wherea
monkey
exhibit
much
less
lung
patholog
specif
shamtreat
monkey
exhibit
larg
multifoc
lung
lesion
desquam
bronchiolar
epitheli
cell
degener
necrosi
alveolar
epithelium
interstiti
edema
multifoc
hemorrhag
strong
inflammatori
infiltr
wherea
monkey
exhibit
mild
moder
expans
parenchym
wall
less
interstiti
edema
significantli
less
inflammatori
cell
infiltr
figur
remain
shamtreat
monkey
sacrif
day
shamtreat
monkey
exhibit
sever
degener
bronchiolar
epitheli
cell
pneumocyt
interstiti
edema
especi
around
blood
vessel
day
wherea
monkey
show
mild
expans
parenchym
wall
less
inflammatori
cell
infiltr
less
pneumocyt
degener
interstiti
edema
observ
figur
previous
describ
semiquantit
histolog
analysi
lung
shamtreat
monkey
day
confirm
treatment
greatli
attenu
lung
histopatholog
figur
clinic
observ
infect
monkey
reveal
shamtreat
monkey
mean
bodi
temperatur
chang
day
respect
figur
exceed
p
monkey
surprisingli
day
mean
viral
titer
homogen
lung
tissu
monkey
approxim
log
lower
titer
shamtreat
monkey
p
figur
indic
lung
viral
replic
reduc
monkey
determin
pharmacokinet
monkey
model
viru
infect
plasma
level
measur
elisa
one
day
treatment
infect
complement
activ
lung
virusinfect
monkey
ac
quantit
revers
transcript
polymeras
chain
reaction
analysi
express
eighteen
sampl
lung
lobe
infect
mockinfect
monkey
day
postinfect
analyz
respect
data
present
foldchang
mean
standard
error
mean
sem
rel
mockinfect
monkey
data
p
determin
student
test
welch
correct
df
plasma
concentr
infect
mockinfect
monkey
variou
time
point
quantit
enzymelink
immunosorb
assay
data
express
mean
sem
n
day
n
day
p
vs
day
determin
analysi
varianc
dunnett
posttest
gl
immunohistochem
analysi
express
lung
infect
mockinfect
monkey
day
postinfect
scale
bar
abbrevi
mrna
messeng
rna
g
semiquantit
histopatholog
analysi
day
h
estain
lung
section
monkey
n
less
lung
damag
untreat
infect
monkey
n
p
determin
student
test
welch
correct
h
chang
bodi
temperatur
mean
standard
error
mean
sem
shamtreat
monkey
indic
time
point
infect
data
shown
calcul
subtract
temperatur
day
n
shamtreat
infect
group
n
infect
group
day
postinfect
n
n
respect
group
day
p
determin
analysi
varianc
bonferroni
posttest
lung
viral
titer
day
postinfect
determin
test
homogen
sampl
collect
lung
lobe
n
shamtreat
infect
monkey
n
infect
monkey
data
express
mean
sem
tissu
cultur
infect
dose
tcid
per
gram
lung
tissu
dot
line
indic
limit
detect
p
determin
student
test
welch
correct
j
concentr
plasma
sampl
infect
monkey
day
circl
show
concentr
individu
monkey
n
day
n
day
treat
monkey
approxim
figur
drop
approxim
day
point
monkey
kill
day
level
remain
monkey
drop
approxim
thu
treatment
dose
decay
rel
slowli
could
potenti
influenc
bioactiv
monkey
model
infect
elucid
role
complement
activ
play
inflammatori
respons
initi
viru
infect
monkey
level
inflammatori
cytokin
chemokin
plasma
shamtreat
monkey
time
measur
elisa
figur
treatment
reduc
inflammatori
respons
monkey
af
quantit
enzymelink
immunosorb
assay
perform
measur
serum
concentr
interleukin
beta
interferon
induc
protein
interleukin
interferon
gamma
tumor
necrosi
factor
alpha
monocyt
chemotact
protein
shamtreat
monkey
mean
standard
error
mean
concentr
indic
time
point
shown
n
shamtreat
infect
group
n
infect
group
day
postinfect
n
n
respect
group
day
p
p
measur
analysi
varianc
bonferroni
posttest
gj
immunohistochem
analysi
macrophag
neutrophil
infiltr
lung
infect
shamtreat
monkey
day
repres
imag
shown
scale
bar
k
l
semiquantit
analysi
macrophag
neutrophil
count
lung
day
postinfect
n
shamtreat
infect
group
n
infect
group
p
determin
student
test
welch
correct
figur
level
studi
inflammatori
mediat
significantli
elev
infect
shamtreat
monkey
interleukin
beta
interferon
induc
protein
monocyt
chemotact
protein
express
peak
earli
day
infect
wherea
interleukin
tumor
necrosi
factor
alpha
interferon
gamma
express
peak
day
declin
day
contrast
monkey
significantli
lower
express
level
inflammatori
mediat
overal
effect
complement
activ
cell
specif
lunginfiltr
macrophag
neutrophil
also
assess
immunohistochem
stain
lung
tissu
section
shamtreat
infect
monkey
day
show
markedli
elev
myeloperoxidas
express
figur
howev
monkey
significantli
fewer
inflammatori
infiltr
cell
lung
especi
neutrophil
figur
data
togeth
show
treatment
markedli
reduc
ali
system
inflamm
induc
viral
infect
infect
influenza
virus
highli
pathogen
avian
influenza
virus
sar
coronaviru
character
dysregul
host
immun
respons
indic
high
level
proor
antiinflammatori
cytokin
although
complement
play
import
role
host
defens
homeostasi
excess
dysregul
activ
pathogen
present
studi
establish
monkey
model
virusinduc
ali
greatli
resembl
clinic
featur
viral
pneumonia
human
lung
blood
infect
monkey
exhibit
extens
complement
activ
accompani
sever
parenchym
lesion
thu
excess
complement
activ
may
contribut
lung
damag
observ
infect
monkey
support
treatment
preclin
monkey
model
substanti
attenu
ali
induc
viru
observ
also
indic
antibodi
treatment
could
effect
intervent
viral
pneumonia
regul
complement
activ
increasingli
recogn
promis
strategi
tackl
inflammatoryrel
diseas
recombin
inhibitor
effect
substitut
therapeut
effect
sever
diseas
includ
hereditari
angioedema
myocardi
infarct
transplant
eculizumab
complementspecif
mab
approv
paroxysm
nocturn
hemoglobinuria
atyp
hemolyt
urem
syndrom
sever
promis
candid
complement
modul
also
test
variou
diseas
model
one
main
anaphylatoxin
produc
multipl
complement
activ
activ
mast
cell
basophil
caus
degranul
turn
lead
vasodil
extravas
fluid
also
particip
endotheli
activ
influenc
express
adhes
molecul
leukocyt
addit
increas
gene
express
protein
synthesi
macrophag
influenc
local
peripher
homeostasi
furthermor
function
import
chemotact
factor
affect
leukocyt
migrat
induc
synthesi
chemotact
factor
sever
line
evid
indic
modul
complement
activ
regul
could
promis
target
treatment
inflammatori
disord
note
evalu
abil
block
activ
assay
perform
zap
sourc
howev
zap
contain
high
concentr
mani
complement
activ
product
includ
fact
complet
block
zapinduc
express
granulocyt
indic
key
driver
granulocyt
activ
inflammatori
set
also
show
could
strongli
inhibit
human
monkey
clinic
sever
case
viru
infect
pneumonia
progress
rapidli
lead
ali
ard
situat
character
dysregul
inflammatori
respons
higher
viru
replic
similarli
virusinfect
monkey
present
studi
present
acut
pneumonia
day
infect
along
signific
system
complement
activ
high
system
level
proinflammatori
cytokin
chemokin
given
import
role
complement
defens
pathogen
upstream
posit
inflammatori
homeostasi
observ
suggest
dysregul
complement
activ
contribut
unbalanc
homeostasi
therebi
induc
proinflammatori
respons
tissu
injuri
studi
also
show
treatment
markedli
decreas
inflammatori
respons
initi
infect
attenu
virusinduc
pneumonia
date
promis
treatment
sever
viral
pneumonia
caus
sar
virus
lack
infecti
system
inflammatori
respons
syndrom
hallmark
diseas
therefor
steroid
wide
use
curb
inflamm
howev
followup
studi
shown
high
dose
steroid
use
treat
sar
caus
osteonecrosi
thu
effect
therapeut
strategi
combat
inflammatori
respons
without
induc
signific
side
effect
need
test
monkey
toxicolog
studi
human
phase
trial
demonstr
good
safeti
profil
permit
use
clinic
trial
clinic
case
sever
influenza
pneumonia
treat
oseltamivir
therefor
worthwhil
determin
potenti
synergist
antivir
effect
oseltamivir
possibl
interact
drug
futur
clinic
studi
conclus
studi
show
regul
complement
activ
may
adjunct
therapeut
option
treatment
sever
pneumonia
induc
infect
approach
may
significantli
improv
outcom
infect
human
especi
combin
antivir
treatment
strategi
supplementari
materi
avail
clinic
infecti
diseas
onlin
http
cidoxfordjournalsorg
supplementari
materi
consist
data
provid
author
publish
benefit
reader
post
materi
copyedit
content
supplementari
data
sole
respons
author
question
messag
regard
error
address
author
